Accel Wealth Management’s AbbVie ABBV Stock Holding History

Accel Wealth Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.35M	Buy	5,358 +494	+10%	+$106K	0.3%	81
2026 Q1	$1.06M	Buy	4,864 +408	+9%	+$90.5K	0.28%	90
2025 Q4	$1.02M	Buy	4,456 +13	+0.3%	+$2.96K	0.28%	90
2025 Q3	$1.03M	Sell	4,443 -387	-8%	-$78.8K	0.3%	84
2025 Q2	$896K	Sell	4,830 -343	-7%	-$63.7K	0.3%	81
2025 Q1	$1.08M	Sell	5,173 -41	-0.8%	-$7.97K	0.39%	72
2024 Q4	$927K	Sell	5,214 -192	-4%	-$35.3K	0.35%	77
2024 Q3	$1.07M	Sell	5,406 -303	-5%	-$56.5K	0.4%	64
2024 Q2	$979K	Buy	5,709 +804	+16%	+$133K	0.39%	64
2024 Q1	$893K	Buy	4,905 +273	+6%	+$47K	0.38%	71
2023 Q4	$718K	Buy	4,632 +115	+3%	+$16.8K	0.36%	74
2023 Q3	$673K	Buy	4,517 +397	+10%	+$58.3K	0.38%	73
2023 Q2	$555K	Buy	4,120 +114	+3%	+$16.7K	0.31%	81
2023 Q1	$638K	Buy	4,006 +341	+9%	+$52.1K	0.26%	91
2022 Q4	$592K	Buy	3,665 +247	+7%	+$37.9K	0.28%	78
2022 Q3	$485K	Buy	3,418 +404	+13%	+$58K	0.26%	83
2022 Q2	$463K	Sell	3,014 -55	-2%	-$8.4K	0.27%	78
2022 Q1	$499K	Buy	3,069 +113	+4%	+$16.4K	0.26%	82
2021 Q4	$400K	Buy	2,956 +652	+28%	+$77K	0.2%	93
2021 Q3	$248K	Sell	2,304 -753	-25%	-$86K	0.16%	113
2021 Q2	$344K	Sell	3,057 -392	-11%	-$44.1K	0.23%	86
2021 Q1	$373K	Buy	3,449 +508	+17%	+$54.3K	0.3%	70
2020 Q4	$315K	Buy	+2,941	New	+$283K	0.29%	71

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Accel Wealth Management's ABBV Position: Q2 2026 in Review

Accel Wealth Management increased its AbbVie (ABBV) stake by 10% in Q2 2026, buying an estimated $106K and bringing the position to 5,358 shares worth $1.35M. The position accounts for 0.3% of the portfolio, ranked #81.

Accel Wealth Management first reported a position in ABBV in Q4 2020 and has held it in 23 quarters since. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Accel Wealth Management held 5,358 shares of AbbVie worth $1.35M as of Q2 2026.
Accel Wealth Management bought 494 AbbVie shares in Q2 2026, an estimated $106K.
AbbVie made up 0.3% of Accel Wealth Management's portfolio in Q2 2026, its #81 holding.
Accel Wealth Management first reported a position in AbbVie in Q4 2020 and has held it in 23 quarters since.
4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Accel Wealth Management's 13F filing for Q2 2026, filed 10 Jul 2026.